Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zovaglutide

Phase 1Peptide

BBeijing QL Biopharmaceutical Co.,Ltd

Zovaglutide is one of 47 small molecule programs targeting Obesity. It is currently in Phase 1.

2

Indications

3

Total Trials

3

Active Trials

46

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityNot yet recruiting

Overweight , ObesityActive, not recruiting

ObesityPhase 1

Not yet recruiting

Overweight , ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

177 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Cagrisema

Eloralintide

Belantamab Mafodotin-Blmf

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Actemra

Avapro

Amidate

Calciferol

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Overweight , Obesity

NCT07443059

Q2 2027

Phase 3Active, not recruiting

Overweight , Obesity

NCT07230119

Q3 2027

Phase 1Not yet recruiting

Obesity

NCT07916194

Clinical

Trials by Indication[1]

Overweight , Obesity2 trials

A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single-dose of Zovaglutide (ZT002 Injection) in Participants With Different Degrees of Renal Insufficiency and Matched Participants With Normal Renal Function

Active, not recruiting·BBeijing QL Biopharmaceutical Co.,Ltd·Phase 1·NCT07443059·40 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.

Active, not recruiting·BBeijing QL Biopharmaceutical Co.,Ltd·Phase 3·NCT07230119·755 enrolled

Obesity1 trial

A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single Dose of Zovaglutide (ZT002 Injection) in Participants With Varying Degrees of Hepatic Impairment and Matched Participants With Normal Hepatic Function

Not yet recruiting·BBeijing QL Biopharmaceutical Co.,Ltd·Phase 1·NCT07916194·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Zovaglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zovaglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zovaglutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing QL Biopharmaceutical Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 1[1]
Company: BBeijing QL Biopharmaceutical Co.,Ltd

Related News